Also trades as: 0VGI.L (LSE) · $vol 0M
TGTX NASDAQ
TG Therapeutics, Inc.
1W: -3.8%
1M: +2.4%
3M: +32.9%
YTD: +34.0%
1Y: +10.6%
3Y: +29.1%
5Y: +14.5%
$38.87
-0.37 (-0.94%)
After Hours: $39.04 (+0.17, +0.44%)
Weekly Expected Move ±10.5%
$31
$35
$40
$44
$48
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (51)
TGTX Stock Rises 29% in 3 Months: Here's What You Should Know
TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 View
Earnings Scheduled For May 6, 2026
TG Therapeutics (TGTX) Q1 2026 Earnings Transcript
TGTX Q1 2025 Earnings Call Transcript
TG Therapeutics outlines $925M 2026 global revenue guidance while targeting ~$220M Q2 U.S. BRIUMVI net revenue
TG Therapeutics (TGTX) Q1 Earnings Lag Estimates
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
Here are the major earnings before the open Wednesday
TG Therapeutics Q1 2026 Earnings Preview
TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update
Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth
TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
TGTX Completes Enrollment in Phase III Study on Subcutaneous Briumvi
SG Americas Securities LLC Acquires 16,982 Shares of TG Therapeutics, Inc. $TGTX
Ocugen (OCGN) Up 2.9% Since Last Earnings Report: Can It Continue?
TG Therapeutics, Inc. $TGTX Shares Bought by JPMorgan Chase & Co.
TG Therapeutics, Inc. $TGTX Shares Purchased by Assenagon Asset Management S.A.
1,922,410 Shares in TG Therapeutics, Inc. $TGTX Acquired by Congress Asset Management Co.
TG Therapeutics secures $750M credit facility with Blue Owl, boosts buyback to $300M
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line
TG Therapeutics: 'Strong Buy' On BRIUMVI's Massive Growth And Possible Expansion
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line
TG Therapeutics GAAP EPS of $0.14 misses by $0.21, revenue of $192.6M misses by $0.74M
TG Therapeutics, Inc. (TGTX) Q4 2025 Earnings Call Transcript
TG Therapeutics (TGTX) Misses Q4 Earnings Estimates
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance
TG Therapeutics Q4 2025 Earnings Preview
TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q4 Release
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of “Moderate Buy” from Brokerages
TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Hussman Strategic Advisors Sells 126,000 TG Therapeutics Shares
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of “Moderate Buy” from Brokerages
TG Therapeutics: The "Exit Velocity" You Can't Ignore (Rating Upgrade)
TG Therapeutics Soars on Strong Revenue Guidance and BRIUMVI Momentum
TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results
TG Therapeutics, Inc. (TGTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
TG Therapeutics Stock Climbs After The Bell: Here's Why
TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
TG Therapeutics: What Wall Street Isn't Telling You
Is the Options Market Predicting a Spike in TG Therapeutics Stock?
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of “Moderate Buy” from Analysts
TG Therapeutics, Inc. $TGTX Shares Sold by Advantage Alpha Capital Partners LP
Creative Planning Sells 7,534 Shares of TG Therapeutics, Inc. $TGTX